查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1735680

全球 BCG 結核病疫苗市場規模（按類型、應用、最終用戶、區域範圍）預測（至 2025 年）

Global BCG Tuberculosis (TB) Vaccine Market Size By Type (Immune, Therapy), By Application (Pediatrics, Adults), By End-User (Hospitals, Clinics) By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

BCG結核病疫苗市場規模及預測

預計 BCG 結核病 (TB) 疫苗市場規模將在 2024 年達到 5,349 萬美元，到 2032 年將達到 7,264 萬美元，在 2026-2032 年預測期內的複合年成長率為 3.90%。

  • BCG（卡介苗）疫苗主要用於治療結核病。它是牛分枝桿菌的弱毒株，牛分枝桿菌與導致結核病的結核菌類似。
  • 這種疫苗在出生後不久就接種，適用於結核病風險較高的嬰兒。卡介苗能夠刺激免疫反應，保護嬰兒免受致命結核病的侵害。它也用於治療膀胱癌。

全球卡介苗結核病疫苗市場動態

影響 BCG 結核病疫苗市場的關鍵市場動態是：

關鍵市場促進因素

  • 全球結核病發生率高企：全球結核病發生率持續居高不下是卡介苗疫苗業務的主要驅動力。根據世界衛生組織（WHO）《2023年全球結核病報告》，預計2022年將有1,060萬人感染結核病，其中130萬人為兒童。分析顯示，結核病仍是世界上最致命的感染疾病之一，2022年造成130萬人死亡。如此巨大的疾病負擔凸顯了有效結核病預防活動，尤其是卡介苗疫苗接種的持續必要性。
  • 政府投入和資金不斷增加：政府對結核病控制的支持和資金籌措不斷增加，正在推動卡介苗市場的發展。據遏制結核病夥伴關係組織 (Stop TB Partnership) 稱，2022 年全球結核病資金籌措將達到 58 億美元，創歷史新高。然而，這仍低於《2018-2022 年全球終止結核病計畫》中提出的 2022 年每年 130 億美元的目標。對消除結核病工作的日益重視預計將增加疫苗接種支出。
  • 新興國家意識的提升和疫苗接種計畫的擴大：疫苗接種計畫的擴大，尤其是在結核病高發的新興國家，正在推動對卡介苗的需求。根據聯合國兒童基金會的數據，全球卡介苗接種覆蓋率已從2000年的85%上升至2019年的88%。在結核病流行的東南亞，2019年卡介苗接種覆蓋率達到了95%。預計此類高負擔地區覆蓋率的提升趨勢將持續下去，從而推動市場成長。

主要挑戰

  • 卡介苗使用相關的副作用：卡介苗的副作用包括淋巴結腫大、高燒和注射部位皮膚感染。雖然這些副作用罕見，但卻阻礙了疫苗的普及和市場的成長。因此，密切監測和控制副作用至關重要。
  • 對卡介苗有效性的擔憂：人們對卡介苗預防新出現的結核病菌株的有效性有疑慮。如果疫苗對這些新出現的結核病菌株無效，將會減少需求並減緩市場成長。需要持續研究和改進，以保持卡介苗的有效性。
  • 供不應求：卡介苗短缺限制了市場擴張。供應鏈問題、生產挑戰或產量短缺導致供不應求，限制了疫苗的供應，尤其是在結核病高負擔國家。需要充足且穩定的供應來滿足全球需求並減少結核病的發生率。

主要趨勢：

  • 高結核病發病率推動全球需求：結核病的全球蔓延仍然是一個重大的公共衛生問題，尤其是在低度開發國家。世界衛生組織 (WHO) 預測，每年將出現數百萬例結核病新病例，這將刺激對卡介苗的需求。世界各國政府認知到結核病控制的重要性，正在進行疫苗宣傳活動，並投資建設醫療機構。
  • 關注兒童疫苗接種計畫：兒童疫苗接種計畫正變得越來越重要，尤其是在結核病高發生率地區。各國政府和衛生組織正優先為新生兒接種疫苗，以預防結核性腦膜炎等嚴重結核病。國際上進行的旨在意識提升的計畫和宣傳活動進一步強化了這一趨勢，從而增加了對卡介苗的需求。
  • 新型候選疫苗的出現：新型及改良型結核病疫苗（包括重組卡介苗和次單位疫苗）目前正在研發中。這些候選疫苗旨在克服現有卡介苗的局限性，並提高其對各種結核病菌株的療效。這些新型疫苗的上市預計將顛覆市場格局，並隨著其臨床試驗和監管核准的推進推動未來成長。

目錄

第1章 BCG結核病（TB）疫苗全球市場介紹

  • 市場介紹
  • 研究範圍
  • 先決條件

第2章執行摘要

第3章：已驗證的市場研究調查方法

  • 資料探勘
  • 驗證
  • 第一手資料
  • 資料來源列表

第4章 BCG結核病疫苗全球市場展望

  • 概述
  • 市場動態
    • 驅動程式
    • 限制因素
    • 機會
  • 波特五力模型
  • 價值鏈分析

5.全球BCG 結核病疫苗市場（按類型）

  • 概述
  • 免疫卡介苗
  • 治療 BCG

6.全球BCG 結核病疫苗市場（依應用）

  • 概述
  • 孩子們
  • 成人

7.全球BCG 結核病疫苗市場（依最終用戶）

  • 概述
  • 醫院
  • 診所

8.全球BCG 結核病疫苗市場（按地區）

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 世界其他地區
    • 拉丁美洲
    • 中東

9. 全球結核病疫苗市場競爭格局

  • 概述
  • 各公司市場排名
  • 主要發展策略

第10章 公司簡介

  • Merck
  • Sanofi Pasteur
  • Japan BCG Lab
  • China National Biotec
  • Serum Institute of India
  • Intervax
  • GSBPL

第11章 附錄

  • 相關調查
簡介目錄
Product Code: 35652

BCG Tuberculosis (TB) Vaccine Market Size and Forecast

BCG Tuberculosis (TB) Vaccine Market size was valued at USD 53.49 Million in 2024 and is projected to reach USD 72.64 Million by 2032, growing at a CAGR of 3.90% from 2026-2032.

  • The BCG (Bacillus Calmette-Guerin) vaccine is primarily used to treat tuberculosis. It is a weakened strain of Mycobacterium bovis, a microbe similar to M. tuberculosis that causes tuberculosis.
  • The vaccine is provided shortly after delivery, particularly to infants at high risk of tuberculosis. The BCG vaccine stimulates an immunological response, protecting babies and young children from deadly types of tuberculosis. It is also used to treat bladder cancer.

Global BCG Tuberculosis (TB) Vaccine Market Dynamics

The key market dynamics that are shaping the BCG Tuberculosis (TB) vaccine market include:

Key Market Drivers

  • High Global Tuberculosis Burden: The persistently high worldwide tuberculosis load is a major driver of the BCG vaccination business. According to the World Health Organization's Global Tuberculosis Report 2023, an estimated 10.6 million individuals became ill with tuberculosis in 2022, including 1.3 million children. According to the analysis, tuberculosis remains one of the world's worst infectious diseases, accounting for 1.3 million fatalities in 2022. This significant disease burden highlights the ongoing need for effective tuberculosis prevention efforts, particularly BCG vaccination.
  • Increasing Government Initiatives and Funding: Growing government support and financing for tuberculosis control initiatives is propelling the BCG vaccine market. According to the Stop TB Partnership, global TB financing reached $5.8 billion in 2022, the highest level reported to date. However, this falls short of the $13 billion yearly expenditure required by 2022, as indicated by the Global Plan to End Tuberculosis 2018-2022. The increased emphasis on tuberculosis elimination is anticipated to enhance expenditure on vaccination efforts.
  • Rising Awareness and Expanding Immunization Programs in Developing Countries: Expanding immunization programs, particularly in developing countries with high tuberculosis burdens, are driving up demand for BCG vaccines. According to UNICEF, global BCG vaccine coverage has increased from 85% in 2000 to 88% in 2019. In South-East Asia, where tuberculosis is endemic, BCG coverage reached 95% in 2019. This trend of expanding coverage in high-burden areas is projected to continue, resulting in market growth.

Key Challenges:

  • Side Effects Associated with the Use of BCG Vaccine: The BCG vaccine has side effects such as swollen lymph nodes, high fever, and skin infections at the injection site. Despite their rarity, these side effects hinder vaccination acceptance and market growth. Careful monitoring and control of any adverse effects is essential.
  • Concerns Regarding the Efficacy of BCG Vaccines: There are questions regarding the BCG vaccine's effectiveness to protect against new tuberculosis strains that have appeared. If the vaccination is ineffective against these new strains, it diminishes demand and slows market growth. Ongoing research and improvement are required to ensure that the BCG vaccine stays effective.
  • Shortage of Supply: A lack of BCG vaccines limits market expansion. Supply chain problems, manufacturing challenges, or underproduction cause shortages and restrict the availability of the vaccine, particularly in high-burden nations. Meeting global demand and reducing tuberculosis require an adequate and stable supply.

Key Trends:

  • Increasing Global Demand Due to High TB Prevalence: The global prevalence of tuberculosis remains a major public health concern, particularly in underdeveloped nations. The World Health Organization (WHO) predicts millions of new tuberculosis infections each year, fueling demand for the BCG vaccine. As governments acknowledge the importance of combating tuberculosis, they are launching vaccination campaigns and investing in healthcare facilities, which are projected to considerably enhance market growth in the future years.
  • Focus on Childhood Immunization Programs: Childhood immunization programs are becoming increasingly important, particularly in areas with high tuberculosis prevalence. Governments and health organizations are prioritizing neonatal vaccination to prevent serious types of tuberculosis, such as TB meningitis. This focus is reinforced by international programs and campaigns focused on raising awareness about tuberculosis prevention, which drives higher demand for the BCG vaccine.
  • Emergence of Novel Vaccine Candidates: New and improved tuberculosis vaccines, such as recombinant BCG vaccines and subunit vaccinations, are now under development. These candidates seek to overcome the limitations of the current BCG vaccine and improve its efficacy against various tuberculosis strains. The prospective launch of these novel vaccines is projected to disrupt the market environment and drive future growth as they go through clinical trials and regulatory approval.

Global BCG Tuberculosis (TB) Vaccine Market Regional Analysis

Here is a more detailed regional analysis of the BCG Tuberculosis (TB) vaccine market:

Asia Pacific:

  • According to Verified Market Research, the Asia Pacific region is estimated to dominate over the forecast period. The Asia Pacific area has a disproportionately high tuberculosis load, fueling up demand for BCG vaccines. According to the World Health Organization's Global Tuberculosis Report 2023, six of the eight countries responsible for two-thirds of global tuberculosis cases in 2022 were in Asia Pacific: India (27%), Indonesia (9.2%), China (7.4%), the Philippines (7%), Pakistan (5.7%), and Bangladesh (3.6%). This high disease load demands ongoing and extended immunization efforts in the region.
  • BCG immunization is primarily targeted at the Asia Pacific region's huge and rising pediatric population. According to the United Nations Population Division, Asia is home to about half of the world's children, with a projected 1.2 billion under the age of 18 in 2020. According to UNICEF, India, which has the region's highest pediatric population, there were roughly 27 million births in 2022. The region's BCG vaccine demand is driven by its large and expanding pediatric population.
  • Furthermore, many Asia Pacific countries are currently working to improve their healthcare infrastructure and increase immunization coverage. For example, according to WHO and UNICEF estimates of national vaccination coverage, BCG vaccine coverage in Southeast Asia increased from 87% in 2000 to 95% by 2022. Since 2000, BCG coverage in the Western Pacific region, which includes China and other East Asian countries, has generally been higher than 95%. This trend of upgrading healthcare systems and extending vaccination programs is a major driver of the BCG vaccine market in the region.

North America:

  • North America is estimated to exhibit significant growth during the forecast period. North America, particularly the United States, sees a lot of immigration from countries with high tuberculosis rates, which drives up the demand for BCG immunization. According to the Centers for Disease Control and Prevention (CDC), 8,300 tuberculosis (TB) infections were reported in the United States in 2022. The CDC also states that foreign-born individuals account for the bulk of tuberculosis cases in the United States, with an incidence rate 14 times higher than that of U.S.-born people in 2022. This demographic pattern highlights the importance of BCG immunization in the region.
  • Furthermore, the BCG vaccine is being utilized as an immunotherapy for bladder cancer, which is generating demand in North America. According to the American Cancer Society, approximately 82,290 new cases of bladder cancer (62,460 in men and 19,830 in women) are expected to be detected in the United States by 2023. The association also believes that bladder cancer is the fourth most frequent malignancy in men. The increasing prevalence of bladder cancer in North America has increased the need for the BCG vaccine as a therapy option.

Europe:

  • Europe region is estimated to exhibit substantial growth during the forecast period. Europe has seen a considerable influx of immigrants from countries with high tuberculosis prevalence, pushing up demand for BCG vaccine. According to the European Centre for Disease Prevention and Control (ECDC), foreign-born people accounted for 29.4% of TB infections in the EU/EEA in 2019. Foreign-born cases ranged from 0% to 95.7% in reporting nations. This demographic transition has led to a greater emphasis on tuberculosis prevention techniques, such as BCG vaccination for high-risk groups.
  • Furthermore, TB vaccine research and development in Europe is on the rise, with enhanced BCG formulations among the highlights. Between 2003 and 2020, the European & Developing Countries Clinical Trials Partnership (EDCTP) contributed more than €157 million in 52 grants for clinical research on tuberculosis vaccines. This investment comprises around 15% of EDCTP's total portfolio. The increased R&D focus is likely to stimulate innovation in the BCG vaccine industry and potentially broaden its applications.

BCG Tuberculosis (TB) Vaccine Market: Segmentation Analysis

The BCG Tuberculosis (TB) Vaccine Market is segmented based on Type, Application, End-User, and Geography.

BCG Tuberculosis (TB) Vaccine Market, By Type

  • Immune BCG
  • Therapy BCG

Based on Type, the market is segmented into Immune BCG and Therapy BCG. The immune BCG segment is estimated to dominate the BCG Tuberculosis (TB) vaccine market due to immune BCG's success in preventing tuberculosis, which has led to widespread acceptance and incorporation into national immunization programs around the world. The lack of alternative vaccinations for immune BCG has further strengthened its standing, as healthcare providers continue to rely on it for tuberculosis prevention.

BCG Tuberculosis (TB) Vaccine Market, By Application

  • Pediatrics
  • Adults

Based on Application, the market is segmented into Pediatrics and Adults. The pediatrics segment is estimated to dominate the BCG Tuberculosis (TB) vaccine market. BCG vaccination is primarily administered to infants and young children because it gives up to 80% protection against severe types of pediatric tuberculosis, such as TB meningitis. Children have a higher risk of contracting tuberculosis than adults. Continuous government measures for tuberculosis immunization in children are helping to drive the segment's growth.

BCG Tuberculosis (TB) Vaccine Market, By End-User

  • Hospitals
  • Clinics

Based on End-User, the BCG Tuberculosis (TB) vaccine market is divided into Hospitals and Clinics. According to VMR analyst, the hospital segment is estimated to dominate the market over the forecast period due to hospitals' extensive healthcare services, which include immunization programs for babies and at-risk groups. Hospitals are frequently equipped with the required infrastructure and skilled personnel to properly deliver the BCG vaccine, making them an ideal location for TB preventive initiatives. Furthermore, hospitals play an important role in handling tuberculosis patients, which helps to secure their market position.

BCG Tuberculosis (TB) Vaccine Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

Based on Geography, the BCG Tuberculosis (TB) vaccine market is classified into North America, Europe, Asia Pacific, and the Rest of the World. The Asia Pacific region is expected to dominate the market during the forecasted period. This domination is mostly due to the high incidence of tuberculosis in countries such as India and China, which account for a sizable proportion of worldwide TB cases. Government attempts to increase vaccine coverage, as well as raising knowledge about tuberculosis prevention, contribute to the region's strong market position. As a result, Asia Pacific is projected to continue to drive the BCG vaccination market.

Key Players

  • The "BCG Tuberculosis (TB) Vaccine Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Merck, Sanofi Pasteur, Japan BCG Lab, China National Biotec, Serum Institute of India, Intervax, and GSBPL.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

  • BCG Tuberculosis (TB) Vaccine Market Recent Developments
  • In July 2021, The New Jersey-based Hackensack Meridian Center for Discovery and Innovation (CDI) announced that it had received USD 6.4 million in funding from the National Institutes of Health to investigate a novel idea for a tuberculosis vaccine. The CDI team has suggested that BCG would be enhanced by designing it to promote B-cell proliferation and survival.
  • In March 2022, The Serum Institute of India Pvt. Ltd. requested the Drugs Controller General of India, seeking the emergency usage of authorization for its recombinant BCG vaccination to combat tuberculosis. Throughout the projected period, the BCG vaccine market will benefit from the approval of this vaccine.
  • In January 2023, The WHO intended to establish a new "TB Vaccine Accelerator Council". The committee will speed up the formation of a high-level coalition comprising international organizations, donors, end users, and governments to identify and address obstacles to the development of tuberculosis vaccines like BCG. It will also help authorize and implement innovative TB vaccines

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL BCG TUBERCULOSIS (TB) VACCINE MARKET

  • 1.1 Introduction of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL BCG TUBERCULOSIS (TB) VACCINE MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL BCG TUBERCULOSIS (TB) VACCINE MARKET, BY TYPE

  • 5.1 Overview
  • 5.2 Immune BCG
  • 5.3 Therapy BCG

6 GLOBAL BCG TUBERCULOSIS (TB) VACCINE MARKET, BY APPLICATION

  • 6.1 Overview
  • 6.2 Pediatrics
  • 6.3 Adults

7 GLOBAL BCG TUBERCULOSIS (TB) VACCINE MARKET, BY END-USER

  • 7.1 Overview
  • 7.2 Hospitals
  • 7.3 Clinics

8 GLOBAL BCG TUBERCULOSIS (TB) VACCINE MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East

9 GLOBAL BCG TUBERCULOSIS (TB) VACCINE MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 Merck
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 Sanofi Pasteur
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 Japan BCG Lab
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 China National Biotec
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 Serum Institute of India
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Intervax
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 GSBPL
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments

11 Appendix

  • 11.1 Related Research